BARROW COUNTY, Ga. — The trial for the father of a teenager accused of opening fire inside his school in 2024, killing four and injuring more, is set to begin on Monday. Colin Gray faces nearly 30 ...

United States Immigration and Customs Enforcement is leveraging Palantir’s generative artificial intelligence tools to sort and summarize immigration enforcement tips from its public submission form, ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

UNDP People for 2030: People are our greatest asset. At UNDP, our People for 2030 strategy recognizes that our greatest asset is our people. As we embrace AI to enhance recruitment and workplace ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

The Command Assessment Program, or CAP, was used to “facilitate(s) the selection of battalion and brigade commanders, brigade command sergeants major, and medical service corps and acquisition corps ...

Defense Secretary Pete Hegseth is expressing support for the Army’s termination of a program that assessed the branch’s leadership selection process. He shared on social media platform X an image of a ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

Add Task & Purpose (opens in a new tab) Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. The Army will ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...